Clinical trial · Interventional
Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear function) and the fatigue and mood of patients with renal cell carcinoma undergoing a therapy with Sunitinib.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endurance exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- Exercise
- interventionNames
- Other: Endurance exercise
- type
- NO_INTERVENTION
- label
- 2
- description
- No structured exercise program
Primary outcomes (1)
- measure
- Fatigue
- timeFrame
- 12 weeks
Secondary outcomes (3)
- measure
- VO2max
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 18 to 75 years * Understanding of written German * Treatment with Sunitinib * Ability to walk Exclusion Criteria: * Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise * BMI \< 18 or \> 30
References
Publications (0)
Data not yet available